Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pemphigus Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

NCT00683930
View directory record Official record
Conditions
Pemphigus Vulgaris (PV)
Interventions
Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910
View directory record Official record
Conditions
Pemphigus
Interventions
Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

NCT00483119
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
intravenous immunoglobulin, cyclophosphamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 1 Interventional Results available

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

NCT03239470
View directory record Official record
Conditions
Pemphigus Foliaceus, Pemphigus Vulgaris
Interventions
Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 1 Interventional

Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders

NCT00278642
View directory record Official record
Conditions
Pemphigus
Interventions
Hematopoietic stem cell transplantation
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Use of KC706 for the Treatment of Pemphigus Vulgaris

NCT00606749
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
KC706
Drug
Lead sponsor
Kemia, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2008 · Synced Jul 22, 2026, 4:59 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Efficacy of Guselkumab in Treating Hailey Hailey Disease

NCT06651489
View directory record Official record
Conditions
Hailey Hailey Disease
Interventions
Guselkumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

NCT02383589
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab, Rituximab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dexamethasone Solution and Dexamethasone in Mucolox™

NCT04540133
View directory record Official record
Conditions
Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
Interventions
dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 22, 2026, 4:59 AM EDT
Completed No phase listed Observational

National Registry for Ichthyosis and Related Disorders

NCT00074685
View directory record Official record
Conditions
Darier Disease, Hailey-Hailey Disease, Hyperkeratosis, Epidermolytic, Ichthyosis, Ichthyosis, Lamellar, Ichthyosis, X-Linked, Keratoderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional

Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris

NCT00135720
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Enbrel (Etanercept)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 22, 2026, 4:59 AM EDT
Recruiting No phase listed Observational

Autoimmune Blistering Diseases Study

NCT02753777
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
Interventions
Questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 4:59 AM EDT
Recruiting Early Phase 1 Interventional

A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease

NCT07717346
View directory record Official record
Conditions
Hailey Hailey Disease, Skin Diseases, Lesion Skin
Interventions
KB111
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study

NCT07151235
View directory record Official record
Conditions
Healthy Participants
Interventions
Simulated wildfire smoke exposure, Clean Air exposure
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598451
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, Placebo, prednisone
Biological · Other · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

NCT01930175
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598477
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 22, 2026, 4:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
DSG3-CAART, CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
13
States / cities
Redwood City, California • Sacramento, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

NCT00429533
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Dapsone
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
8
States / cities
Chicago, Illinois • Detroit, Michigan • Camden, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2007 · Synced Jul 22, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 4:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 4:59 AM EDT
Recruiting Phase 1 Interventional

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562
View directory record Official record
Conditions
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions
AB-101, Rituximab, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Jul 22, 2026, 4:59 AM EDT